Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,847 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07295262RecruitingEarly Phase 1
New imaging to guide liver cancer surgery
This trial tests a new imaging technique that uses a special dye combined with a chemotherapy drug to help surgeons see and remove liver cancer more precisely during surgery. It is for people with a first-time, single liver tumor that is small and can be surgically removed.
Chengdu, SichuanAges 18–75 - NCT07288801RecruitingPhase 4
Vitamin D to prevent preeclampsia again in pregnancy
This trial tests whether taking vitamin D can help pregnant women who had preeclampsia before avoid getting it again. It may protect both you and your baby.
Multan, Punjab ProvinceAges 20–45 - NCT07289997RecruitingPhase 2
Combination therapy for advanced AFP-producing gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
Shijiazhuang, HebeiAges 18 years+ - NCT07295340Recruiting
New imaging dye test for liver cancer detection
This trial tests a special dye that targets liver cancer cells to help surgeons see tumor edges more clearly during surgery. It may help ensure all cancer is removed in one operation.
Chengdu, SichuanAges 18–80 - NCT07295821RecruitingPhase 2
Osimertinib for stage III lung cancer patients who can't have chemo
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
BeijingAges 18 years+ - NCT07288216RecruitingPhase 2
Switching to KPL-387 alone for well-controlled pericarditis
This study tests whether a new drug, KPL-387, can keep your pericarditis under control as your only treatment, after you have been stable on other medicines. It is for people whose pericarditis is well controlled now but who have had flares in the past.
Phoenix, ArizonaAges 18–80 - NCT04305808Recruiting
Study of gut, bladder, and vaginal bacteria in recurrent UTIs
This study looks at the bacteria living in the vagina, urine tract, and stool to learn why some women get repeated urinary tract infections (UTIs). The results may help doctors better prevent or treat UTIs in the future.
Jerusalem, JerusalemAges Any age - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT07285213RecruitingPhase 2
Preventing C. diff return with an antibody
This study tests a new antibody (AZD5148) to prevent C. diff infection from coming back. If you have a current C. diff infection and are being treated with antibiotics, you may be able to join.
Phoenix, ArizonaAges 18 years+ - NCT07284121Recruiting
Patient satisfaction and safety of Atezolizumab in routine care
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
KremsAges 18 years+ - NCT07283822RecruitingPhase 2
Pembrolizumab and Ruxolitinib for Lymphoma
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
New York, New YorkAges 18–95 - NCT07282184RecruitingPhase 1/Phase 2
Liver cancer risk prediction and treatment study
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
Wuhan, HubeiAges 18–75 - NCT07282912RecruitingPhase 2
Extra treatment for certain digestive cancers with undetectable ctDNA
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
New Haven, ConnecticutAges 18–80 - NCT07282262RecruitingPhase 2
Ivosidenib for advanced bile duct cancer with IDH1 mutation
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
BeijingAges 18–80 - NCT03902912RecruitingPhase 3
Prednisolone treatment to help women after repeated miscarriages
This trial tests whether taking prednisolone, a steroid medicine, can improve immune cell activity in the uterus in women who have had 3 or more miscarriages. If it works, it could help reduce the chance of future pregnancy loss.
Hong KongAges 18–40 - NCT07276529Recruiting
Magnet procedure safety trial for colon surgery patients
This trial tests a new magnet device to connect sections of the colon after surgery. It may be an option for people who need part of their colon removed and are otherwise in good health.
Orlando, FloridaAges 22 years+ - NCT06889623Recruiting
Chemotherapy right after surgery for high-risk bladder cancer
This trial tests whether giving chemotherapy immediately after surgery can help people with high-risk, non-muscle-invasive bladder cancer. It aims to reduce the chance of the cancer coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07278440Recruiting
Exercise program for brain tumor patients and their partners
This study tests if a home exercise program can improve mental and physical health for people with brain tumors and their live-in partners. Both of you will be guided through exercise sessions together over video.
Portland, OregonAges 18 years+ - NCT06641713Recruiting
Comparing two liver cancer treatments for large tumors
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
Beijing, Beijing MunicipalityAges 18–75 - NCT06766266RecruitingPhase 1
Irinotecan and Epirubicin for recurring bladder cancer
This trial tests a combination of two chemotherapy drugs (irinotecan and epirubicin) for people whose bladder cancer has come back after prior treatment with a similar drug. The goal is to see if this combination can help shrink or control the cancer.
ChongqingAges 18 years+ - NCT07264569RecruitingPhase 1/Phase 2
Testing a new drug for lung cancer that has spread to the brain or spinal fluid
This trial tests a new drug called BioTTT001 for people with non-small cell lung cancer (NSCLC) that has spread to the fluid around the brain or the lining of the brain (leptomeninges). The goal is to see if the drug is safe and can help control the cancer.
Zhengzhou, HenanAges 18–70 - NCT07266298RecruitingPhase 1
T-cell therapy for advanced solid tumors
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
Beijing, Beijing MunicipalityAges 18–75 - NCT07265921RecruitingPhase 1
Study of SIM0609 for advanced solid tumors
This trial tests an investigational new drug, SIM0609, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see early signs that it might help slow or shrink tumors.
BeijingAges 18 years+ - NCT07263906RecruitingPhase 1
LILRA6 car-t therapy for resistant or relapsed aml
This early-phase trial tests a new cell therapy (CAR-T) that targets a protein called LILRA6 on leukemia cells. It's designed for people whose acute myeloid leukemia (AML) has come back or hasn't responded to standard treatments.
Hangzhou, ZhejiangAges 18–75
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,847 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.